Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital

Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.

Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.

Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.

SERVICIO

Financiamiento, deuda y mercados de capitales

PARTES

“The COVID-19 pandemic has clearly highlighted the challenges and gaps in our industry in Europe. It makes our mission to make scarce medicines available more important than ever. We want to respond to this situation strongly by growing organically as well as through acquisitions in Europe. With the capital, the know-how and the broad (international) network of Gilde Buy Out Partners, Gilde Healthcare, and our existing investor Quadrum Capital, we can achieve this in both a socially responsible as well as financially sound manner.”

Jan Willem Popma

Director, Ace Pharmaceuticals BV

Contáctese con el equipo de la transacción

Bas Stoetzer

Partner

Amsterdam, Países Bajos
Oaklins Netherlands

Ver perfil Contáctenos

Niels Vermuë

Director Asociado

Amsterdam, Países Bajos
Oaklins Netherlands

Ver perfil Contáctenos

Transacciones relacionadas

Pharma-Skan & Skan-Medic have been acquired by Brygge Partners

Salud

Pharma-Skan & Skan-Medic have been acquired by Brygge Partners

Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.

He-Man Dual Controls has been acquired by Lagercrantz UK Limited

Private Equity | Automotriz | Maquinaria y Componentes Industriales

He-Man Dual Controls has been acquired by Lagercrantz UK Limited

Lagercrantz UK Limited has acquired 100% of the shares in HM Holding Limited (He-Man Dual Controls), a leader in supplemental control systems for vehicles.

Manolete Partners plc has completed a successful debt refinancing

Servicios de Soporte Comercial | Servicios Financieros

Manolete Partners plc has completed a successful debt refinancing

Manolete Partners plc has signed a new revolving credit facility (RCF) with its existing provider, HSBC. The new RCF provides Manolete with the same level of facility as the previous arrangement, at US$22.6 million (£17.5 million), but with a reduced margin and lower non-utilization fee. The facility has a term of 3.25 years, with the option to extend for an additional year on the same terms.